Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Update on the role of lenalidomide in patients with multiple myeloma
Sarah A. Holstein, Vera J. Suman, Philip L. McCarthy
Therapeutic Advances in Hematology (2018) Vol. 9, Iss. 7, pp. 175-190
Open Access | Times Cited: 46

Showing 1-25 of 46 citing articles:

Emerging immunotherapies in multiple myeloma
Urvi A. Shah, Sham Mailankody
BMJ (2020), pp. m3176-m3176
Open Access | Times Cited: 113
New drugs are not enough‑drug repositioning in oncology: An update
Romina Armando, Diego Mengual G�mez, Daniel E. Gómez
International Journal of Oncology (2020)
Open Access | Times Cited: 80
Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse
Meletios Α. Dimopoulos, Katja Weisel, Philippe Moreau, et al.
Leukemia (2020) Vol. 35, Iss. 6, pp. 1722-1731
Open Access | Times Cited: 50
Emerging Therapeutic Strategies to Overcome Drug Resistance in Multiple Myeloma
Lorraine N. Davis, Daniel W. Sherbenou
Cancers (2021) Vol. 13, Iss. 7, pp. 1686-1686
Open Access | Times Cited: 45
Second primary malignancies in multiple myeloma: A review
Christina Poh, Theresa H.M. Keegan, Aaron S. Rosenberg
Blood Reviews (2020) Vol. 46, pp. 100757-100757
Open Access | Times Cited: 47
CD38 antibody re-treatment in daratumumab-refractory multiple myeloma after time on other therapies
Olivia Perez de, Lauren T. Reiman, David Jayabalan, et al.
Blood Advances (2023) Vol. 7, Iss. 21, pp. 6430-6440
Open Access | Times Cited: 14
An overview of multiple myeloma: A monoclonal plasma cell malignancy’s diagnosis, management, and treatment modalities
Maisa Siddiq Abduh
Saudi Journal of Biological Sciences (2023) Vol. 31, Iss. 2, pp. 103920-103920
Open Access | Times Cited: 12
Carfilzomib, daratumumab, and dexamethasone (KdD) vs. lenalidomide-sparing pomalidomide-containing triplet regimens for relapsed/refractory multiple myeloma: an indirect treatment comparison
Katja Weisel, Meletios Α. Dimopoulos, Meral Beksaç, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2024) Vol. 65, Iss. 4, pp. 481-492
Open Access | Times Cited: 3
An Antibody‐Drug Conjugate for Multiple Myeloma Prepared by Multi‐Arm Linkers
Yueh‐Hsiang Yu, Wei‐Ting Tian, Cédric Grauffel, et al.
Advanced Science (2024) Vol. 11, Iss. 20
Open Access | Times Cited: 3
Potent Activity of an Anti-ICAM1 Antibody–Drug Conjugate against Multiple Myeloma
Daniel W. Sherbenou, Su Yang, Christopher R. Behrens, et al.
Clinical Cancer Research (2020) Vol. 26, Iss. 22, pp. 6028-6038
Open Access | Times Cited: 27
Anticancer drugs repurposed for Alzheimer’s disease: a systematic review
Antonio Ancidoni, Ilaria Bacigalupo, Giulia Remoli, et al.
Alzheimer s Research & Therapy (2021) Vol. 13, Iss. 1
Open Access | Times Cited: 23
Chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma
Taewoong Choi, Yubin Kang
Pharmacology & Therapeutics (2021) Vol. 232, pp. 108007-108007
Open Access | Times Cited: 20
Reshaping the tumor microenvironment: The versatility of immunomodulatory drugs in B-cell neoplasms
Hao Guo, Jingyi Yang, Haoran Wang, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 13
c‐FOS is an integral component of the IKZF1 transactivator complex and mediates lenalidomide resistance in multiple myeloma
Naoki Osada, Jiro Kikuchi, Hidekatsu Iha, et al.
Clinical and Translational Medicine (2023) Vol. 13, Iss. 8
Open Access | Times Cited: 7
Promising Anti-Mitochondrial Agents for Overcoming Acquired Drug Resistance in Multiple Myeloma
Vanessa Innao, Vincenzo Rizzo, Andrea Gaetano Allegra, et al.
Cells (2021) Vol. 10, Iss. 2, pp. 439-439
Open Access | Times Cited: 17
Double-drug loading upconversion nanoparticles for monitoring and therapy of a MYC/BCL6-positive double-hit diffuse large B-cell lymphoma
Yulu Yang, Rui Chen, Yi Gong, et al.
Biomaterials (2022) Vol. 287, pp. 121607-121607
Closed Access | Times Cited: 9
A Combination of the Immunotherapeutic Drug Anti-Programmed Death 1 with Lenalidomide Enhances Specific T Cell Immune Responses against Acute Myeloid Leukemia Cells
Barbara‐ann Guinn, Patrick J. Schuler, Hubert Schrezenmeier, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 11, pp. 9285-9285
Open Access | Times Cited: 5
Interferon regulatory factor 4 as a therapeutic target in adult T-cell leukemia lymphoma
Daniel A. Rauch, Sydney L. Olson, John C. S. Harding, et al.
Retrovirology (2020) Vol. 17, Iss. 1
Open Access | Times Cited: 13
Design, synthesis and biological evaluation of thioether-containing lenalidomide and pomalidomide derivatives with anti-multiple myeloma activity
Yuhong Wang, Mi Tian, Yiming Li, et al.
European Journal of Medicinal Chemistry (2020) Vol. 209, pp. 112912-112912
Closed Access | Times Cited: 12
LY103, a pomalidomide derivative, alleviates taxol resistance in NSCLC via energy metabolism crosstalk and tumor microenvironment intervention
Xing Wang, Xiaohan Wang, Yongfei Zhao, et al.
Bioorganic Chemistry (2023) Vol. 136, pp. 106558-106558
Closed Access | Times Cited: 4
Pomalidomide, Bortezomib, and Dexamethasone in Lenalidomide-Pretreated Multiple Myeloma: A Subanalysis of OPTIMISMM by Frailty and Bortezomib Dose Adjustment
Albert Oriol, Meletios Α. Dimopoulos, Fredrik Schjesvold, et al.
Clinical Lymphoma Myeloma & Leukemia (2023) Vol. 24, Iss. 3, pp. 165-176.e4
Open Access | Times Cited: 4
Pomalidomide/Daratumumab/Dexamethasone in Relapsed or Refractory Multiple Myeloma: Final Overall Survival From MM-014
Nizar J. Bahlis, Christy Samaras, Donna Reece, et al.
Clinical Lymphoma Myeloma & Leukemia (2024) Vol. 24, Iss. 12, pp. 852-862
Open Access | Times Cited: 1
Real-world treatment patterns and clinical outcomes in patients with multiple myeloma previously treated with lenalidomide and an anti-CD38 monoclonal antibody
Karthik Ramasamy, Ravi Vij, David J. Kuter, et al.
Clinical Lymphoma Myeloma & Leukemia (2024)
Closed Access | Times Cited: 1
Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide‐pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics
Paul G. Richardson, Fredrik Schjesvold, Katja Weisel, et al.
European Journal Of Haematology (2021) Vol. 108, Iss. 1, pp. 73-83
Open Access | Times Cited: 10
Transient Viral Activation in Human T Cell Leukemia Virus Type 1-Infected Macaques Treated With Pomalidomide
Anna Gutowska, Katherine McKinnon, Sarkis Sarkis, et al.
Frontiers in Medicine (2022) Vol. 9
Open Access | Times Cited: 7
Page 1 - Next Page

Scroll to top